* evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers
* characterize the single-dose pharmacokinetics (PK) of ALN-4285
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2
* Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator
Exclusion Criteria:
* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)
* Has total bilirubin \>ULN
* Has systolic blood pressure \>140 mmHg and/or a diastolic blood pressure \>90 mmHg
* Has an estimated glomerular filtration (eGFR) of \<90 mL/min/1.73m\^2 at screening
* Has received an investigational agent within the last 30 days or 5 half-lives
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.